摘要
本文用放射性同位素双标记示踪技术观察了血脂平,大槐合剂两类降脂中药对大鼠LDL经受体与非受体途径代谢的影响。结果表明,血脂平和大槐合剂分别使LDL经受体途径的FCR增加43%和35%,非受体途径的FCR也增加了34%和40%。这两类降脂中药促进LDL自血浆中清除的作用均比安妥明强。提示这两类降脂中药降血浆TC和LDL-C的作用在于促进LDL经受体与非受体途径降解。本文结果也提示,将免疫刺激剂与胆汁酸络合剂合并应用于降血脂,可为高胆固醇血症和动脉粥样硬化的防治提供一条新途径。
The effects of two lipids lowering drugs, Xu Zhiping and Mixtura Dai Huai, on the LDL metabolism by receptor dependent and independent pathways in experimental hypercholesterolemia rats were obsvered using radioisotopic double-labelling trace technique. The results showed that in the receptor dependent or independent pathways, the FCR of LDL was increased by 43% and 34% respectively in Xu Zhiping group, and by 35% and 40% respectively in Mixtura Dai Huai group as compared with controls. Both drugs appeared to be more effective than colifibrate, in promoting clearance of LDL from plasma suggesting that the role in reducing plasma TC and LDL-C was depended on accelerating LDL degradation through both receptor dependent and independent pathways. It was also suggested that immune stimulus in combination with cholagogus may become a new way for prevention of hypercholesterolemia and atherosclerosis.
出处
《中国病理生理杂志》
CAS
CSCD
北大核心
1991年第6期577-580,共4页
Chinese Journal of Pathophysiology
